{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:33:29Z","timestamp":1761896009568},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40262-014-0229-z","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T13:12:51Z","timestamp":1421759571000},"page":"663-670","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis"],"prefix":"10.1007","volume":"54","author":[{"given":"Kristin C. Carlsson","family":"Petri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisbeth V.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,21]]},"reference":[{"key":"229_CR1","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224\u201330.","journal-title":"Diabetes Care"},{"key":"229_CR2","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","volume":"52","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046\u201355.","journal-title":"Diabetologia"},{"key":"229_CR3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84\u201390.","journal-title":"Diabetes Care"},{"key":"229_CR4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","volume":"26","author":"M Marre","year":"2009","unstructured":"Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26\u00a0weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268\u201378.","journal-title":"Diabet Med"},{"key":"229_CR5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473\u201381.","journal-title":"Lancet"},{"key":"229_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39\u201347.","journal-title":"Lancet."},{"key":"229_CR7","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","volume":"375","author":"RE Pratley","year":"2010","unstructured":"Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447\u201356.","journal-title":"Lancet."},{"key":"229_CR8","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1177\/0091270011430504","volume":"52","author":"SH Ingwersen","year":"2012","unstructured":"Ingwersen SH, Khurana M, Madabushi R, Watson E, Jonker DM, Le Thi TD, et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol. 2012;52:1815\u201323.","journal-title":"J Clin Pharmacol"},{"key":"229_CR9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpeds.2004.12.042","volume":"146","author":"O Pinhas-Hamiel","year":"2005","unstructured":"Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693\u2013700.","journal-title":"J Pediatr"},{"key":"229_CR10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/jps.23085","volume":"101","author":"J Vaidyanathan","year":"2012","unstructured":"Vaidyanathan J, Choe S, Sahajwalla CG. Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. J Pharm Sci. 2012;101:1659\u201371.","journal-title":"J Pharm Sci"},{"key":"229_CR11","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1109333","volume":"366","author":"P Zeitler","year":"2012","unstructured":"Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247\u201356.","journal-title":"N Engl J Med"},{"issue":"10","key":"229_CR12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/dia.2013.0366","volume":"16","author":"DJ Klein","year":"2014","unstructured":"Klein DJ, Battelino T, Chatterjee DJ, Hale PM, Chang CT, Arslanian SA. Liraglutide trial in pediatric type 2 diabetes: safety, tolerability and pharmacokinetics\/pharmacodynamics. Diabetes Technol Ther. 2014;16(10):679\u20138.","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl 1","key":"229_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","volume":"67","author":"RF Cock De","year":"2011","unstructured":"De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl 1):5\u201316.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"229_CR14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","volume":"15","author":"K Hermansen","year":"2013","unstructured":"Hermansen K, Baekdal TA, During M, Pietraszek A, Mortensen LS, Jorgensen H, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, crossover trial. Diabetes Obes Metab. 2013;15(11):1040\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"229_CR15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1463-1326.2010.01322.x","volume":"13","author":"L Morrow","year":"2011","unstructured":"Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab. 2011;13:75\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"229_CR16","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Last amended by the 59th WMA General Assembly, Seoul. 2008. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/ ."},{"key":"229_CR17","unstructured":"International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline For Good Clinical Practice E6 (R1), current Step 4 version, dated 10 June 1996. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf ."},{"key":"229_CR18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","volume":"45","author":"H Agerso","year":"2002","unstructured":"Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195\u2013202.","journal-title":"Diabetologia"},{"key":"229_CR19","unstructured":"US Food and Drug Administration. Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072114.pdf . Accessed 30 May 2013."},{"key":"229_CR20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pst.403","volume":"10","author":"C Hu","year":"2011","unstructured":"Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2011;10:14\u201326.","journal-title":"Pharm Stat"},{"key":"229_CR21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/0091270010366146","volume":"51","author":"W Knebel","year":"2011","unstructured":"Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR, Meng X. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16\u00a0years. J Clin Pharmacol. 2011;51:333\u201345.","journal-title":"J Clin Pharmacol"},{"key":"229_CR22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2337\/dc06-1554","volume":"30","author":"M Gottschalk","year":"2007","unstructured":"Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30:790\u20134.","journal-title":"Diabetes Care"},{"key":"229_CR23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/2230-8229.98279","volume":"19","author":"MA Al-Shareef","year":"2012","unstructured":"Al-Shareef MA, Sanneh AF, Aljoudi AS. Clinical effect of metformin in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis. J Family Community Med. 2012;19:68\u201373.","journal-title":"J Family Community Med"},{"key":"229_CR24","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1542\/peds.2006-0690","volume":"118","author":"AD Liese","year":"2006","unstructured":"Liese AD, D\u2019Agostino RB Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118:1510\u20138.","journal-title":"Pediatrics"},{"key":"229_CR25","unstructured":"European Medicines Agency. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003066.pdf . Accessed 16 Aug 2013."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0229-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0229-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0229-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:20Z","timestamp":1551204740000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0229-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,21]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0229-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,21]]}}}